HA
BBIO icon

HHLR Advisors’s BridgeBio Pharma BBIO Stock Holding History

HHLR Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,023,950
Closed -$28.1M – 50
2024
Q4 		$28.1M Hold
1,023,950
– – 0.97% 16
2024
Q3 		$26.1M Sell
1,023,950
-366,703
-26% -$9.63M 0.57% 18
2024
Q2 		$35.2M Buy
1,390,653
+23,164
+2% +$633K 0.87% 14
2024
Q1 		$42.3M Sell
1,367,489
-23,751
-2% -$808K 0.92% 17
2023
Q4 		$56.2M Sell
1,391,240
-1,391,510
-50% -$41.8M 1.13% 16
2023
Q3 		$73.4M Sell
2,782,750
-210,697
-7% -$5.98M 1.64% 12
2023
Q2 		$51.5M Sell
2,993,447
-984,963
-25% -$14.8M 1.1% 18
2023
Q1 		$66M Sell
3,978,410
-1,208,815
-23% -$14.1M 1.17% 16
2022
Q4 		$39.5M Sell
5,187,225
-174,789
-3% -$1.67M 0.83% 20
2022
Q3 		$53.3M Hold
5,362,014
– – 1.4% 18
2022
Q2 		$48.7M Hold
5,362,014
– – 1.04% 21
2022
Q1 		$54.4M Hold
5,362,014
– – 1.14% 21
2021
Q4 		$89.4M Hold
5,362,014
– – 1.38% 15
2021
Q3 		$251M Hold
5,362,014
– – 3.29% 9
2021
Q2 		$327M Hold
5,362,014
– – 3.36% 7
2021
Q1 		$330M Buy
5,362,014
+650,410
+14% +$42.6M 3.26% 9
2020
Q4 		$335M Hold
4,711,604
– – 2.66% 10
2020
Q3 		$177M Hold
4,711,604
– – 1.34% 14
2020
Q2 		$154M Hold
4,711,604
– – 1.4% 15
2020
Q1 		$137M Buy
4,711,604
+322,914
+7% +$10M 1.84% 15
2019
Q4 		$154M Hold
4,388,690
– – 1.92% 15
2019
Q3 		$94.2M Buy
4,388,690
+2,035,790
+87% +$56.3M 1.3% 20
2019
Q2 		$63.5M Buy
+2,352,900
New +$64.1M 1.42% 21

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

HHLR Advisors's BBIO Position: Q1 2025 in Review

HHLR Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 1,023,950 shares — an estimated $28.1M sold.

HHLR Advisors first reported a position in BBIO in Q2 2019 and held it in 23 quarters. The position peaked at $335M in Q4 2020. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • HHLR Advisors reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
  • HHLR Advisors sold 1,023,950 BridgeBio Pharma shares in Q1 2025, an estimated $28.1M.
  • HHLR Advisors first reported a position in BridgeBio Pharma in Q2 2019 and held it in 23 quarters.
  • HHLR Advisors's BridgeBio Pharma position peaked at $335M in Q4 2020.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on HHLR Advisors's 13F filing for Q1 2025, filed 15 May 2025.